文献速递妇科

妇科肿瘤免疫治疗期间静脉血栓栓塞的发生率与临床影响

Incidence and clinical impact of venous thromboembolism during immunotherapy for gynecologic cancer.
PubMed 文献 · Gynecol Oncol · 2026-10-22

这项单中心回顾性队列纳入2017年1月至2026年4月接受免疫检查点抑制剂治疗的458例妇科恶性肿瘤患者,8.1%发生静脉血栓栓塞,中位发生时间为用药后1.43个月,以深静脉血栓和肺栓塞为主,多数需急诊或住院并导致免疫治疗延迟。

要点

  • 免疫检查点抑制剂治疗妇科肿瘤患者静脉血栓栓塞发生率为8.1%。
  • 血栓多在免疫治疗后早期出现,中位时间1.43个月。
  • 多数血栓事件需急诊评估或住院,并可导致免疫治疗延迟。

核心结论

  • 接受免疫检查点抑制剂治疗的妇科肿瘤患者中静脉血栓栓塞发生率为8.1%,发生时间早且临床负担显著。

研究设计与样本

  • 单中心回顾性队列研究,纳入2017年1月至2026年4月接受免疫检查点抑制剂治疗的458例妇科恶性肿瘤患者。

主要发现

  • 458例中37例(8.1%)发生静脉血栓栓塞,深静脉血栓占48.6%(n=18),肺栓塞占40.5%(n=15)。
  • 从免疫检查点抑制剂启动至血栓的中位时间为1.43个月(IQR,0.70-2.93)。
  • 发生血栓者中子宫内膜癌最常见,占54.1%(n=20)。
  • 发生血栓者接受免疫单药治疗的比例更高(64.9% vs. 44.9%,p=0.020),且既往治疗线数更少(2.4 vs. 3.3,p=0.008)。
  • 64.9%(n=24)的血栓事件需急诊评估,59.5%(n=22)需住院,24.3%(n=9)导致免疫治疗延迟,接受抗凝者中18.9%(n=7)发生突破性血栓。

临床怎么用

  • 启动免疫检查点抑制剂时应向妇科肿瘤患者告知静脉血栓栓塞风险并提高警惕。
  • 免疫治疗早期需关注血栓症状,尤其对接受单药治疗或既往治疗线数较少的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the incidence, risk factors, and clinical outcomes associated with venous thromboembolism (VTE) in patients with gynecologic cancer treated with immune checkpoint inhibitors (ICI). METHODS: This retrospective cohort study included patients with gynecologic malignancies treated with ICI at a single institution between January 2017 and April 2026. The primary outcome was the development of VTE from ICI initiation through one month after the final cycle. Incidence, clinical characteristics, risk factors, and healthcare utilization were evaluated. RESULTS: Among 458 patients who received ICI therapy, 37 (8.1%) experienced a VTE. Deep vein thrombosis was the most common event (48.6%, n = 18), followed by pulmonary embolism (40.5%, n = 15). The median time from ICI initiation to VTE was 1.43 months (IQR, 0.70-2.93). Endometrial cancer was the most common disease site among patients with VTE (54.1%, n = 20). Smoking history differed significantly between groups (p < 0.01). ICI monotherapy was more common among patients who experienced VTE compared with those who did not (64.9% vs. 44.9%, p = 0.020), and patients with VTE had received fewer total lines of therapy (2.4 vs. 3.3, p = 0.008). Most events required emergency department evaluation (64.9%, n = 24) and hospitalization (59.5%, n = 22), and ICI therapy was delayed in 24.3% (n = 9) of cases. Breakthrough thrombosis was observed in 18.9% (n = 7) of patients receiving anticoagulation. CONCLUSION: VTE occurred in 8.1% of gynecologic cancer patients receiving ICI, was early in onset, and carried significant clinical burden. These data can guide provider awareness and patient counseling when initiating ICI in this population.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Abdeen CS, Sciuva J, O'Connor RM, et al. Incidence and clinical impact of venous thromboembolism during immunotherapy for gynecologic cancer. Gynecol Oncol. 2026. PMID: 42913285. doi:10.1016/j.ygyno.2026.10.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。